Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study.

Trial Profile

Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2018

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Mar 2018 Results (n=195) post-hoc analysis performed on a subset of patient with gene expression profiling on tissues from this trial to identify markers associated with progression-free survival (PFS) and treatment response, were published in the European Journal of Cancer.
    • 26 Sep 2016 Results for secondary endpoints HRQOL and neurocognitive functioning, published in the Lancet Oncology Journal.
    • 26 Sep 2016 Results of this trial, published in the Lancet Oncology Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top